Page 151 - Human Use News Today

Positive opinion paves way for third indication in Europe for Kymriah, a potentially definitive single infusion CAR-T cell therapy treatment optionCHMP opinion based on Phase II global ELARA trial demonstrating

Investegate announcements from F. Hoffmann-La Roche Ltd, CHMP recommends EU approval of Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma

Polivy plus R-CHP showed first clinically meaningful improvement in PFS with comparable safety in people with previously untreated diffuse large B-cell lymphoma over the standard of care in... | March 25, 2022

Opinion Granted Based on Positive Results From Phase 3 KEYNOTE-826 Trial ... | March 25, 2022

25.03.2022 - Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), for CABOMETYX ... Seite 1

Recommendation based on data from the COSMIC-311 Phase III trial, in which Cabometyx (cabozantinib) demonstrated a 78% reduction in risk of disease progression or death versus placebo1 Disclaimer:

This article summarises the regulation around prohibited and controlled advertising in Turkey.

Leukine is FDA Approved to Treat Acute Radiation Syndrome (ARS) and Recommended in EMEA/CPMP Guidance to Treat Systemic Sulfur Mustard (HD) Gas Exposure Tanner Pharma Group, an international distributor

Tanner Pharma Group, an international distributor of essential medicines, announced that it has significantly increased its inventory of Leukine ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.